At a glance
ClinicalIndex Comparison Record- ✓Histologically or cytologically confirmed adenocarcinoma of GE junction or stomach, unresectable/beyond surgical resection
- ✓Measurable disease: ≥20 mm by conventional imaging or ≥10 mm by spiral CT
- ✓ECOG performance status ≤2 (Karnofsky ≥60%)
- ✓Life expectancy >6 weeks
- ✕Chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas/mitomycin C) prior to entry or unrecovered adverse events from prior therapy
- ✕Concurrent investigational agents, radiation therapy, or chemotherapy; prior photodynamic therapy within 4 weeks unless for esophageal obstruction relief
- ✕Known brain metastases
- ✕Uncontrolled intercurrent illness: ongoing/active infection, symptomatic CHF, unstable angina, cardiac arrhythmia, psychiatric illness/social situations limiting compliance
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of PS-341 Alone or in Combination With Irinotecan in Patients With Adenocarcinoma of the Gastroesophageal Junction (GEJ) or Stomach
In Brief
A Phase 2 clinical trial evaluating bortezomib and irinotecan for Adenocarcinoma of the Gastroesophageal Junction and 7 related conditions. Completed, enrolled 41 participants across 1 site.
Detailed Summary
This phase II trial is studying how well bortezomib with or without irinotecan works in treating patients with gastroesophageal junction or stomach cancer that can not be removed by surgery. Bortezomib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Drugs used in chemotherapy such as irinotecan use different ways to stop tumor cells from dividing so they stop growing or die. Combining bortezomib with irinotecan may kill more tumor cells.
Study Details
Timeline
Interventions
Given IV
Given IV